Beigene Ltd (NASDAQ:BGNE) CMO Jane Huang sold 2,500 shares of the company’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $134.74, for a total value of $336,850.00. Following the sale, the chief marketing officer now directly owns 328,873 shares of the company’s stock, valued at $44,312,348.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Jane Huang also recently made the following trade(s):
- On Monday, July 29th, Jane Huang sold 10,130 shares of Beigene stock. The shares were sold at an average price of $134.54, for a total value of $1,362,890.20.
- On Thursday, June 27th, Jane Huang sold 430 shares of Beigene stock. The shares were sold at an average price of $124.52, for a total value of $53,543.60.
- On Monday, May 20th, Jane Huang sold 300 shares of Beigene stock. The shares were sold at an average price of $130.12, for a total value of $39,036.00.
Shares of Beigene stock opened at $141.19 on Friday. The stock has a 50-day moving average price of $129.48 and a 200 day moving average price of $129.91. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.46 and a quick ratio of 7.47. Beigene Ltd has a 1 year low of $105.19 and a 1 year high of $182.30.
Institutional investors have recently made changes to their positions in the stock. Capital Investment Advisory Services LLC acquired a new position in Beigene in the 2nd quarter worth about $26,000. Advisor Group Inc. increased its position in Beigene by 301.4% in the 4th quarter. Advisor Group Inc. now owns 285 shares of the company’s stock worth $40,000 after purchasing an additional 214 shares during the last quarter. Quadrant Capital Group LLC increased its position in Beigene by 131.8% in the 1st quarter. Quadrant Capital Group LLC now owns 364 shares of the company’s stock worth $47,000 after purchasing an additional 207 shares during the last quarter. Riverhead Capital Management LLC increased its position in Beigene by 28.6% in the 2nd quarter. Riverhead Capital Management LLC now owns 450 shares of the company’s stock worth $56,000 after purchasing an additional 100 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its position in Beigene by 1,500.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 592 shares of the company’s stock worth $73,000 after purchasing an additional 555 shares during the last quarter.
BGNE has been the subject of several analyst reports. Sanford C. Bernstein initiated coverage on Beigene in a report on Tuesday, June 4th. They set an “outperform” rating and a $201.00 target price for the company. Zacks Investment Research downgraded Beigene from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Maxim Group set a $170.00 target price on Beigene and gave the company a “buy” rating in a report on Friday, August 9th. BidaskClub raised Beigene from a “hold” rating to a “buy” rating in a research note on Wednesday, July 31st. Finally, Piper Jaffray Companies reissued a “buy” rating on shares of Beigene in a research note on Thursday, June 20th. One analyst has rated the stock with a sell rating, one has given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $181.28.
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
Recommended Story: Diversification in Investing
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.